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Abstract
Peroral cholangioscopy (POCS) and percutaneous transhepatic cholangioscopy (PTCS) were first developed in the 1970s,
and technical developments and clinical applications have taken place gradually ever since. POCS is used to diagnose small
mucosal biliary lesions in non-icteric patients and early malignant changes in patients with persistent primary sclerosing
cholangitis (PSC). Although PTCS is a more invasive diagnostic procedure than POCS, it has the advantage of precise
diagnosis with mapping biopsy in defining the proximal and distal extension of superficially spreading cholangiocarcinoma
(CCA) or mucin-producing CCA, which is predominantly found in papillary type CCA. POCS is significantly superior to
ERCP in distinguishing between malignant and benign dominant bile duct stenoses in patients with PSC. The positive rate
of PTCS biopsy for CCA is 96%, while morbidity and mortality of PTCS are 9% and 0%, respectively. Although magnetic
resonance (MR) cholangiography may replace PTCS in determining the longitudinal spread of infiltrating type hilar CCA,
the accuracy of MR cholangiography in papillary type hilar CCA is significantly lower than that of PTCS.
Key Words: Cholangioscopy, Cholangiocarcinoma, Cholangiography
Introduction
Biliary endoscopy has been used as a therapeutic
procedure to remove gallstones retained in the com-
mon bile duct and intrahepatic duct through a
choledochotomy during biliary surgery. And a fiber-
optic choledochoscope developed in the 1970s has
been used postoperatively through a T-tube sinus tract
to remove retained stones [1].
Peroral cholangioscopy was first reported in 1976
[2,3]. Percutaneous transhepatic cholangioscopy was
also developed in the 1970s [4], and technical
developments and clinical use of this technique have
gradually progressed and the value of PTCS for
cholangiocarcinoma (CCA) has been reported [5,6].
Indications
Peroral cholangioscopy (POCS) is used to make a
definitive diagnosis of extrahepatic CCA and recent
development of diagnostic techniques has made it
possible to detect a minute lesion in the bile duct of
non-icteric patients. Small polyps and small stenotic
lesions can be distinguished by endoscopic observa-
tion and biopsy [7,8]. Distal extension of the tumor is
defined by cholangioscopic biopsy, especially in the
case of superficially spreading CCA [6]. Recently, a
new imaging technique, ‘‘narrow band imaging’’
(NBI), has been developed providing better visualiza-
tion of fine mucosal structures and tumor vessels [9].
Although POCS is less invasive than PTCS, proximal
extension of the tumor cannot be examined in
common types of CCA obstructing the bile duct.
PTCS has also been used to differentiate the biliary
strictures and polyps [1012] and to make a pre-
operative definitive diagnosis of more difficult CCA
located not only in the extrahepatic bile duct but also
in the intrahepatic bile duct [6,13,14].
Usefulness
POCS is advantageous in the definitive diagnosis of
small mucosal biliary lesions detected in non-icteric
patients [8] and helpful in diagnosing early malignant
changes in patients with persistent primary sclerosing
cholangitis [12]. Although PTCS is a more invasive
diagnostic procedure than POCS, it has the advantage
of precise preoperative diagnosis in the case of
patients with more difficult CCA. Mapping biopsy
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for superficially spreading CCA is helpful in defining
the proximal and distal extension of the tumor
[5,6,1416] and in designing a type of resection with
negative surgical margins. Furthermore, in special
cases of mucin-producing intrahepatic CCA, PTBD
followed by PTCS is important when evaluating the
progress of cancer along the intrahepatic segmental
duct and extrahepatic bile duct and in providing an
expected type of hepatobiliary resection with or with-
out pancreatoduodenectomy [1719].
Results
POCS by using NBI is significantly more useful than
conventional POCS in identifying the surface struc-
ture and vessels of the lesions (pB0.01 and pB0.05)
[9]. In terms of its sensitivity, specificity, accuracy,
positive predictive valve, and negative predictive
value, POCS is significantly superior to ERCP in
distinguishing between malignant and benign domi-
nant bile duct stenosis in patients with primary
sclerosing cholangitis [12]. PTCS observation with
biopsy offers a high positive rate in malignant biliary
diseases. Correct results for bile duct carcinoma have
been obtained in 96% of patients (101 from 111), and
negative biopsy findings in 10 patients with diffusely
infiltrating CCA (Table I). The morbidity and mor-
tality rates of PTBD (501 patients) and PTCS (295
patients) were 9% (46 patients) and 0%, respectively
(Table II) [14].
Routine histological examination, including P53
immunostaining and telomerase activity, in cholan-
gioscopic biopsy specimens increases both sensitivity
and specificity in determining the spread of CCA
[20,21]. Similarly to distal bile duct cancer, hilar
CCA also shows several types of morphology and
superficially spreading cancer in more than 10% of
resected patients. This type of cancer is found
predominantly in papillary type CCA [22]. Although
MR cholangiography may supersede PTCS in deter-
mining the longitudinal spread of infiltrating type
hilar CCA, the accuracy of MR cholangiography in
papillary type hilar CCA is significantly lower than
that of PTCS [23].
Consensus statement
. Cholangioscopy should be performed for pre-
operative staging of CCA when papillary type
CCA or mucin-producing CCA is suspected in
conventional cholangiography or MR cholangio-
graphy, because these types of CCA are predo-
minantly associated with superficially spreading
carcinoma, which should be precisely diagnosed
with mapping biopsy to design a type of resective
surgery.
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